Mark Higgins Selected Research

indacaterol

9/2014	Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.
2/2011	Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
11/2010	24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol.
10/2010	Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
9/2010	Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.
9/2010	Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
7/2010	Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
6/2010	Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
6/2010	Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
3/2010	Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Higgins Research Topics

Disease

17	Cystic Fibrosis (Mucoviscidosis) 11/2022 - 01/2011
13	Chronic Obstructive Pulmonary Disease (COPD) 09/2014 - 01/2007
7	Asthma (Bronchial Asthma) 09/2014 - 10/2007
2	Infections 01/2020 - 01/2018
2	Disease Progression 01/2020 - 01/2018
2	Cough 01/2011 - 03/2010
1	Inflammation (Inflammations) 11/2022
1	Surgical Wound Infection 10/2018
1	Constipation 01/2018
1	Intestinal Obstruction (Obstruction, Intestinal) 01/2018
1	Kaposi Varicelliform Eruption (Eczema Herpeticum) 01/2018
1	Chronic Cough 01/2018
1	Femoral Fractures (Femoral Fracture) 12/2016
1	Osteoporosis 12/2016
1	Pain (Aches) 12/2016
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2014
1	Pseudomonas Infections 01/2011

Drug/Important Bio-Agent (IBA)

18	indacaterolIBA 09/2014 - 01/2007
13	ivacaftorIBA 11/2022 - 12/2014
13	Bronchodilator Agents (Bronchodilators)IBA 09/2014 - 01/2007
3	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2016 - 12/2008
3	Tobramycin (Nebcin)FDA LinkGeneric 03/2014 - 01/2011
3	PowdersIBA 03/2014 - 01/2011
3	Salmeterol Xinafoate (Serevent)FDA Link 02/2011 - 09/2010
3	Formoterol Fumarate (Oxis)FDA Link 06/2010 - 02/2009
2	Pharmaceutical PreparationsIBA 03/2014 - 01/2011
2	SolutionsIBA 03/2014 - 01/2011
2	Tiotropium Bromide (Spiriva)FDA Link 10/2010 - 07/2010
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 11/2022
1	TrypsinogenIBA 11/2022
1	lumacaftorIBA 11/2022
1	Biomarkers (Surrogate Marker)IBA 11/2022
1	ivacaftor drug combination tezacaftorIBA 01/2021
1	tezacaftorIBA 01/2021
1	Methicillin (Metin)FDA Link 10/2018
1	Alanine Transaminase (SGPT)IBA 01/2018
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2018
1	Aspartic Acid (Aspartate)FDA Link 01/2018
1	Diphosphonates (Bisphosphonates)IBA 12/2016
1	Alendronate (Alendronate Sodium)FDA LinkGeneric 12/2016
1	ChloridesIBA 07/2015
1	Proteins (Proteins, Gene)FDA Link 03/2015
1	CarbonIBA 01/2014
1	Fluticasone (Cutivate)FDA LinkGeneric 09/2010
1	Albuterol (Salbutamol)FDA LinkGeneric 09/2010
1	Beclomethasone (Beclometasone)FDA Link 12/2007
1	GoldIBA 01/2007
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2007

Therapy/Procedure

4	Dry Powder Inhalers 09/2010 - 12/2007
1	Hand Hygiene 01/2020
1	Therapeutics 12/2016